1) renin angiotensin converting enzyme inhibitor
肾素血管紧张素转换酶抑制剂(RACI)
2) Angiotensin converting enzyme inhibitors
血管紧张素转换酶抑制剂
1.
Angiotensin converting enzyme inhibitors(ACEI)have been extensively applied to treat hypertension and diabetic nephropathy in the chronic renal failure patients.
血管紧张素转换酶抑制剂(ACEI)已被广泛应用于治疗慢性肾衰竭患者的高血压以及糖尿病肾病等疾病,但是近年来研究报道关于ACEI是否影响促红细胞生成素(EPO)治疗慢性肾衰竭的疗效还存在争议,本文就其可能的机制以及一些临床研究作如下综述。
2.
The data including primary kidney diseases and cardiovascular diseases of the patients and whether they took angiotensin converting enzyme inhibitors(ACELI)in the past three months were reviewed.
调查患者原发病、心血管并发症及是否应用血管紧张素转换酶抑制剂(ACEI)治疗。
3.
Objective: To study the prevalence of cough and withdrawal of angiotensin converting enzyme inhibitors (ACEI) in treatment of hypertension.
目的:研究血管紧张素转换酶抑制剂(ACE抑制剂)治疗高血压的咳嗽发生率和停药率。
3) angiotensin converting enzyme inhibitor
血管紧张素转换酶抑制剂
1.
The purification and identification of angiotensin converting enzyme inhibitor from Guangxi cobra venom;
广西眼镜蛇毒中血管紧张素转换酶抑制剂的分离纯化及鉴定
2.
Screening of angiotensin converting enzyme inhibitors from Salvia miltiorrhizae;
从丹参中筛选血管紧张素转换酶抑制剂
3.
The influence of renal function on renoprotective effect of angiotensin converting enzyme inhibitors (ACEI) in chronic glomerulonephritis patients;
肾功能状态对3种血管紧张素转换酶抑制剂肾保护作用的影响
4) angiotensin-converting enzyme inhibitor
血管紧张素转换酶抑制剂
1.
Mechanism of angiotensin-converting enzyme inhibitor in inhibiting intimal hypertrophy of injured rat artery;
血管紧张素转换酶抑制剂抑制大鼠损伤动脉内膜肥厚的机制
2.
Methods:Forty male Wistar rats were divided into four groups,Group A(n=10),B(n=10)medicine group,angiotensin-converting enzyme inhibitor(inhibace) 10 mg/kg/day was given orally to rats by gastric gavage in the morning once a day.
25%百特透析液,同时血管紧张素转换酶抑制剂一平苏10 mg/kg。
3.
Angiotensin-converting enzyme inhibitor/angiotensin Ⅱ receptor antagonist,which improves insulin sensitivity,decreases cardiovascular morbidity and the incidence of type 2 diabetes.
血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂可通过改善胰岛素敏感性,使心血管疾病的发病率及新发2型糖尿病的发病率下降。
5) angiotensin-converting enzyme inhibitors
血管紧张素转换酶抑制剂
1.
Aim: To determine mechanisms of cardioprotection induced by combination angiotensin-converting enzyme inhibitors(ACEI)with subthreshold preconditioning after activation of mitochondrial ATP-sensitive potassium(mitoK ATP )channel.
目的探讨血管紧张素转换酶抑制剂(ACEI)和阈下缺血预处理联合预处理诱导的心肌保护作用中mi-toK_(ATP)通道激动后的作用机制。
2.
The aim of the present study was to determine whether angiotensin-converting enzyme inhibitors (ACEI) could contributeto the protective effects of preconditioning, and to explore its underlying mechanism.
实验采用离体大鼠心脏Langendorff灌流模型,观察含巯基(卡托普利)和不含巯基(培哚普利拉)的两种血管紧张素转换酶抑制剂(angiotensin-convertingenzymeinhibitors,ACEI)对抗心肌缺血的作用,并探讨一氧化氮(nitricoxide,NO)和线粒体ATP敏感性钾通道(mitochondrialATP-sensitivepotassiumchannel,mitoKATPchannel)是否参与ACEI的心肌保护作用。
3.
Objective To investigate the effect of angiotensin-converting enzyme inhibitors on incidence of aspiratory pneumonia in elderly hypertensive stroke patients with chronic obstructive pulmonary disease.
目的观察合并高血压的脑卒中并发稳定期慢性阻塞性肺疾病患者应用血管紧张素转换酶抑制剂(ACEI)类降压药对其预防吸入性肺炎的影响。
6) ACEI
血管紧张素转换酶抑制剂
1.
Whether ACEI should be used on low-risk patients with coronary artery disease-expounding on IMAGINE studies;
低危冠心病患者是否应该使用血管紧张素转换酶抑制剂——IMAGINE研究解读
2.
Effects of ACEI and Zhenju Jiangya tablet on ET, NO in type 2 diabetes;
血管紧张素转换酶抑制剂及珍菊降压片对2型糖尿病内皮素、一氧化氮的影响
3.
Investigate of angiotensin-converting enzyme inhibitors( ACEI) and vasopeptidas inhibitors(VPI);
血管紧张素转换酶抑制剂和血管肽酶抑制剂研究进展
补充资料：血管紧张素转换酶抑制剂
血管紧张素转换酶抑制剂
converting enzyme inhibitor of angiotensin
能够抑制血管紧张素转换酶的活性、使血管紧张素Ⅰ不能转换成血管紧张素Ⅱ的物质，如替普罗肽(又称SQ20881）及卡托普利(又称SQ14225）。用于肾血管性高血压及高血压危象。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条